Coherus Oncology (CHRS) Asset Utilization Ratio (2014 - 2026)
Coherus Oncology (CHRS) posted Asset Utilization Ratio of 0.18 for Q1 2026, up 64.28% sequentially from 0.11 in Q4 2025, and up 131.31% YoY from 0.08 in Q1 2025.
Coherus Oncology (CHRS) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Coherus Oncology has reported Asset Utilization Ratio for 13 years, with the latest figure at 0.18 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 131.31% year-over-year to 0.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.18 (up 131.31% YoY) and the FY2025 annual result came in at 0.12, up 143.74% from the prior year.
- Asset Utilization Ratio climbed to 0.18 in Q1 2026 per CHRS's latest filing, from 0.11 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.48 in Q2 2022 and troughed at 0.06 in Q4 2024.
- A 5-year average of 0.28 and a median of 0.33 in 2024 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2024 and 2026: Asset Utilization Ratio tumbled 86.95% in 2024, then jumped 131.31% in 2026.
- Over 5 years, Asset Utilization Ratio stood at 0.41 in 2022, then rose by 3.65% to 0.42 in 2023, then sank by 86.95% to 0.06 in 2024, then surged by 96.66% to 0.11 in 2025, then soared by 64.28% to 0.18 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.18, 0.11, and 0.08 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.22 |
| Mar 31, 2026 | 0.18 |
| Dec 31, 2025 | 0.11 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.08 |
| Dec 31, 2024 | 0.06 |
| Sep 30, 2024 | 0.19 |
| Jun 30, 2024 | 0.25 |
| Mar 31, 2024 | 0.33 |
| Dec 31, 2023 | 0.42 |
| Sep 30, 2023 | 0.40 |
| Jun 30, 2023 | 0.42 |
| Mar 31, 2023 | 0.42 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.44 |
| Jun 30, 2022 | 0.48 |
| Mar 31, 2022 | 0.48 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 0.49 |